McGill researchers identify protein target for more effective glioblastoma treatment

Glioblastoma patients face poor prognosis with current treatments, as tumors typically recur within months despite surgery, radiation, and chemotherapy.

For decades, glioblastoma has followed a cruel rhythm: treatment, brief reprieve, return. Researchers at McGill University have now identified a protein called galectin1 as a key sustainer of the cancer's most resilient cells — the stem cells that quietly rebuild the tumor after every assault. By suppressing this protein in preclinical models and combining that suppression with radiation therapy, the team observed tumors halting their growth and patients living longer, offering a new way of understanding the disease not as a mass to be destroyed, but as a system to be dismantled.

McGill researchers identify protein target for more effective glioblastoma treatment

Cobertura Relacionada

Receba o Register no seu e-mail